rethinkPeptides Search
Menu
Research citation

Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [18F]SiTATE.

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [18F]SiTATE.

European radiology, 34(11), 7222-7232

Citation

Ebner, R; Lohse, A; Fabritius, M P; Rübenthaler, J; Wängler, C; Wängler, B; Schirrmacher, R; Völter, F; Schmid, H P; Unterrainer, L M; Öcal, O; Hinterberger, A; Spitzweg, C; Auernhammer, C J; Geyer, T; Ricke, J; Bartenstein, P; Holzgreve, A; Grawe, F. (2024). Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [18F]SiTATE.. European radiology, 34(11), 7222-7232. https://doi.org/10.1007/s00330-024-10788-3